APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Monoclonal Antibodies

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Cancer Monoclonal Antibodies Industry Growth and Trends Forecast to 2032

22 December 202571 pages

Choose your research edition.

Industry ResearchCancer Monoclonal Antibodies Industry Research Report 2026108 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Monoclonal Antibodies Industry Growth and Trends Forecast to 203271 pages · $3,450 USDMarket StructureGlobal Cancer Monoclonal Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Monoclonal Antibodies Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Monoclonal Antibodies Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Cancer Monoclonal Antibodies market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Cancer Monoclonal Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Cancer Monoclonal Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Monoclonal Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Cancer Monoclonal Antibodies include Takeda Pharmaceuticals, Amgen, F. Hoffmann-La Roche and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Cancer Monoclonal Antibodies market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Cancer Monoclonal Antibodies market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Cancer Monoclonal Antibodies market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Cancer Monoclonal Antibodies.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Cancer Monoclonal Antibodies market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Cancer Monoclonal Antibodies Market by Company

Takeda Pharmaceuticals

Amgen

F. Hoffmann-La Roche

Bristol-Myers Squibb

Cancer Monoclonal Antibodies Segment by Type

Chimeric and Humanised Antibodies

Fully Humanized Antibodies

Murine Antibodies

Others

Cancer Monoclonal Antibodies Segment by Application

Blood

Breast

Liver

Brain

Cancer Monoclonal Antibodies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Monoclonal Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Monoclonal Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Monoclonal Antibodies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Cancer Monoclonal Antibodies manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Cancer Monoclonal Antibodies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Chimeric and Humanised Antibodies Table 2. Major Company of Fully Humanized Antibodies Table 3. Major Company of Murine Antibodies Table 4. Major Company of Others Table 5. Global Cancer Monoclonal Antibodies Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Cancer Monoclonal Antibodies Sales by Type (2021-2026) & (k units) Table 7. Global Cancer Monoclonal Antibodies Sales Market Share in Volume by Type (2021-2026) Table 8. Global Cancer Monoclonal Antibodies Sales by Type (2021-2026) & (US$ Million) Table 9. Global Cancer Monoclonal Antibodies Sales Market Share in Value by Type (2021-2026) Table 10. Global Cancer Monoclonal Antibodies Price by Type (2021-2026) & (US$/unit) Table 11. Global Cancer Monoclonal Antibodies Sales by Type (2027-2032) & (k units) Table 12. Global Cancer Monoclonal Antibodies Sales Market Share in Volume by Type (2027-2032) Table 13. Global Cancer Monoclonal Antibodies Sales by Type (2027-2032) & (US$ Million) Table 14. Global Cancer Monoclonal Antibodies Sales Market Share in Value by Type (2027-2032) Table 15. Global Cancer Monoclonal Antibodies Price by Type (2027-2032) & (US$/unit) Table 16. North America Cancer Monoclonal Antibodies Sales by Type (2021-2026) & (k units) Table 17. North America Cancer Monoclonal Antibodies Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Cancer Monoclonal Antibodies Sales by Type (2021-2026) & (k units) Table 19. Europe Cancer Monoclonal Antibodies Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Cancer Monoclonal Antibodies Sales by Type (2021-2026) & (k units) Table 21. Asia-Pacific Cancer Monoclonal Antibodies Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Cancer Monoclonal Antibodies Sales by Type (2021-2026) & (k units) Table 23. Latin America Cancer Monoclonal Antibodies Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Cancer Monoclonal Antibodies Sales by Type (2021-2026) & (k units) Table 25. Middle East and Africa Cancer Monoclonal Antibodies Sales by Type (2021-2026) & (US$ Million) Table 26. Cancer Monoclonal Antibodies Industry Trends Table 27. Cancer Monoclonal Antibodies Industry Drivers Table 28. Cancer Monoclonal Antibodies Industry Opportunities and Challenges Table 29. Cancer Monoclonal Antibodies Industry Restraints Table 30. Global Cancer Monoclonal Antibodies Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Cancer Monoclonal Antibodies Revenue Market Share by Company (2021-2026) Table 32. Global Cancer Monoclonal Antibodies Sales by Company (2021-2026) & (k units) Table 33. Global Cancer Monoclonal Antibodies Sales Share by Company (2021-2026) Table 34. Global Cancer Monoclonal Antibodies Market Price by Company (2021-2026) & (US$/unit) Table 35. Global Cancer Monoclonal Antibodies Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Cancer Monoclonal Antibodies Major Company Production Sites and Headquarters Table 37. Global Cancer Monoclonal Antibodies Company, Product Type & Application Table 38. Global Cancer Monoclonal Antibodies Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Cancer Monoclonal Antibodies by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Cancer Monoclonal Antibodies Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Cancer Monoclonal Antibodies Sales by Region (2021-2026) & (k units) Table 43. Global Cancer Monoclonal Antibodies Sales Market Share in Volume by Region (2021-2026) Table 44. Global Cancer Monoclonal Antibodies Sales by Region (2021-2026) & (US$ Million) Table 45. Global Cancer Monoclonal Antibodies Sales Market Share in Value by Region (2021-2026) Table 46. Global Cancer Monoclonal Antibodies Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 47. Global Cancer Monoclonal Antibodies Sales by Region (2027-2032) & (k units) Table 48. Global Cancer Monoclonal Antibodies Sales Market Share in Volume by Region (2027-2032) Table 49. Global Cancer Monoclonal Antibodies Sales by Region (2027-2032) & (US$ Million) Table 50. Global Cancer Monoclonal Antibodies Sales Market Share in Value by Region (2027-2032) Table 51. Global Cancer Monoclonal Antibodies Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 52. Global Cancer Monoclonal Antibodies Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Cancer Monoclonal Antibodies Sales by Application (2021-2026) & (k units) Table 54. Global Cancer Monoclonal Antibodies Sales Market Share in Volume by Application (2021-2026) Table 55. Global Cancer Monoclonal Antibodies Sales by Application (2021-2026) & (US$ Million) Table 56. Global Cancer Monoclonal Antibodies Sales Market Share in Value by Application (2021-2026) Table 57. Global Cancer Monoclonal Antibodies Price by Application (2021-2026) & (US$/unit) Table 58. Global Cancer Monoclonal Antibodies Sales by Application (2027-2032) & (k units) Table 59. Global Cancer Monoclonal Antibodies Sales Market Share in Volume by Application (2027-2032) Table 60. Global Cancer Monoclonal Antibodies Sales by Application (2027-2032) & (US$ Million) Table 61. Global Cancer Monoclonal Antibodies Sales Market Share in Value by Application (2027-2032) Table 62. Global Cancer Monoclonal Antibodies Price by Application (2027-2032) & (US$/unit) Table 63. North America Cancer Monoclonal Antibodies Sales by Application (2021-2026) & (k units) Table 64. North America Cancer Monoclonal Antibodies Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Cancer Monoclonal Antibodies Sales by Application (2021-2026) & (k units) Table 66. Europe Cancer Monoclonal Antibodies Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Cancer Monoclonal Antibodies Sales by Application (2021-2026) & (k units) Table 68. Asia-Pacific Cancer Monoclonal Antibodies Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Cancer Monoclonal Antibodies Sales by Application (2021-2026) & (k units) Table 70. Latin America Cancer Monoclonal Antibodies Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Cancer Monoclonal Antibodies Sales by Application (2021-2026) & (k units) Table 72. Middle East and Africa Cancer Monoclonal Antibodies Sales by Application (2021-2026) & (US$ Million) Table 73. Takeda Pharmaceuticals Company Information Table 74. Takeda Pharmaceuticals Business Overview Table 75. Takeda Pharmaceuticals Cancer Monoclonal Antibodies Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Takeda Pharmaceuticals Cancer Monoclonal Antibodies Product Portfolio Table 77. Takeda Pharmaceuticals Recent Development Table 78. Amgen Company Information Table 79. Amgen Business Overview Table 80. Amgen Cancer Monoclonal Antibodies Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Amgen Cancer Monoclonal Antibodies Product Portfolio Table 82. Amgen Recent Development Table 83. F. Hoffmann-La Roche Company Information Table 84. F. Hoffmann-La Roche Business Overview Table 85. F. Hoffmann-La Roche Cancer Monoclonal Antibodies Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. F. Hoffmann-La Roche Cancer Monoclonal Antibodies Product Portfolio Table 87. F. Hoffmann-La Roche Recent Development Table 88. Bristol-Myers Squibb Company Information Table 89. Bristol-Myers Squibb Business Overview Table 90. Bristol-Myers Squibb Cancer Monoclonal Antibodies Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Bristol-Myers Squibb Cancer Monoclonal Antibodies Product Portfolio Table 92. Bristol-Myers Squibb Recent Development Table 93. North America Cancer Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 94. North America Cancer Monoclonal Antibodies Sales by Country (2021-2026) & (k units) Table 95. North America Cancer Monoclonal Antibodies Sales Market Share by Country (2021-2026) Table 96. North America Cancer Monoclonal Antibodies Sales Forecast by Country (2027-2032) & (k units) Table 97. North America Cancer Monoclonal Antibodies Sales Market Share Forecast by Country (2027-2032) Table 98. North America Cancer Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 99. North America Cancer Monoclonal Antibodies Market Size by Country (2021-2026) & (US$ Million) Table 100. North America Cancer Monoclonal Antibodies Market Share by Country (2021-2026) Table 101. North America Cancer Monoclonal Antibodies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 102. North America Cancer Monoclonal Antibodies Market Share Forecast by Country (2027-2032) Table 103. Europe Cancer Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 104. Europe Cancer Monoclonal Antibodies Sales by Country (2021-2026) & (k units) Table 105. Europe Cancer Monoclonal Antibodies Sales Market Share by Country (2021-2026) Table 106. Europe Cancer Monoclonal Antibodies Sales Forecast by Country (2027-2032) & (k units) Table 107. Europe Cancer Monoclonal Antibodies Sales Market Share Forecast by Country (2027-2032) Table 108. Europe Cancer Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 109. Europe Cancer Monoclonal Antibodies Market Size by Country (2021-2026) & (US$ Million) Table 110. Europe Cancer Monoclonal Antibodies Market Share by Country (2021-2026) Table 111. Europe Cancer Monoclonal Antibodies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 112. Europe Cancer Monoclonal Antibodies Market Share Forecast by Country (2027-2032) Table 113. Asia-Pacific Cancer Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 114. Asia-Pacific Cancer Monoclonal Antibodies Sales by Country (2021-2026) & (k units) Table 115. Asia-Pacific Cancer Monoclonal Antibodies Sales Market Share by Country (2021-2026) Table 116. Asia-Pacific Cancer Monoclonal Antibodies Sales Forecast by Country (2027-2032) & (k units) Table 117. Asia-Pacific Cancer Monoclonal Antibodies Sales Market Share Forecast by Country (2027-2032) Table 118. Asia-Pacific Cancer Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 119. Asia-Pacific Cancer Monoclonal Antibodies Market Size by Country (2021-2026) & (US$ Million) Table 120. Asia-Pacific Cancer Monoclonal Antibodies Market Share by Country (2021-2026) Table 121. Asia-Pacific Cancer Monoclonal Antibodies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 122. Asia-Pacific Cancer Monoclonal Antibodies Market Share Forecast by Country (2027-2032) Table 123. Latin America Cancer Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 124. Latin America Cancer Monoclonal Antibodies Sales by Country (2021-2026) & (k units) Table 125. Latin America Cancer Monoclonal Antibodies Sales Market Share by Country (2021-2026) Table 126. Latin America Cancer Monoclonal Antibodies Sales Forecast by Country (2027-2032) & (k units) Table 127. Latin America Cancer Monoclonal Antibodies Sales Market Share Forecast by Country (2027-2032) Table 128. Latin America Cancer Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. Latin America Cancer Monoclonal Antibodies Market Size by Country (2021-2026) & (US$ Million) Table 130. Latin America Cancer Monoclonal Antibodies Market Share by Country (2021-2026) Table 131. Latin America Cancer Monoclonal Antibodies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. Latin America Cancer Monoclonal Antibodies Market Share Forecast by Country (2027-2032) Table 133. Middle East and Africa Cancer Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 134. Middle East and Africa Cancer Monoclonal Antibodies Sales by Country (2021-2026) & (k units) Table 135. Middle East and Africa Cancer Monoclonal Antibodies Sales Market Share by Country (2021-2026) Table 136. Middle East and Africa Cancer Monoclonal Antibodies Sales Forecast by Country (2027-2032) & (k units) Table 137. Middle East and Africa Cancer Monoclonal Antibodies Sales Market Share Forecast by Country (2027-2032) Table 138. Middle East and Africa Cancer Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Middle East and Africa Cancer Monoclonal Antibodies Market Size by Country (2021-2026) & (US$ Million) Table 140. Middle East and Africa Cancer Monoclonal Antibodies Market Share by Country (2021-2026) Table 141. Middle East and Africa Cancer Monoclonal Antibodies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Middle East and Africa Cancer Monoclonal Antibodies Market Share Forecast by Country (2027-2032) Table 143. Key Raw Materials Table 144. Raw Materials Key Suppliers Table 145. Cancer Monoclonal Antibodies Distributors List Table 146. Cancer Monoclonal Antibodies Customers List Table 147. Research Programs/Design for This Report Table 148. Authors List of This Report Table 149. Secondary Sources Table 150. Primary Sources List of Figures Figure 1. Cancer Monoclonal Antibodies Image Figure 2. Global Cancer Monoclonal Antibodies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Monoclonal Antibodies Market Size (2021-2032) & (US$ Million) Figure 4. Global Cancer Monoclonal Antibodies Sales (2021-2032) & (k units) Figure 5. Chimeric and Humanised Antibodies Image Figure 6. Global Chimeric and Humanised Antibodies Sales YoY Growth (2021-2032) & (k units) Figure 7. Fully Humanized Antibodies Image Figure 8. Global Fully Humanized Antibodies Sales YoY Growth (2021-2032) & (k units) Figure 9. Murine Antibodies Image Figure 10. Global Murine Antibodies Sales YoY Growth (2021-2032) & (k units) Figure 11. Others Image Figure 12. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 13. Global Cancer Monoclonal Antibodies Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Cancer Monoclonal Antibodies Market Share by Type 2025 VS 2032 Figure 15. North America Cancer Monoclonal Antibodies Sales Market Share in Volume by Type in 2025 Figure 16. North America Cancer Monoclonal Antibodies Sales Market Share in Value by Type in 2025 Figure 17. Europe Cancer Monoclonal Antibodies Sales Market Share in Volume by Type in 2025 Figure 18. Europe Cancer Monoclonal Antibodies Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Cancer Monoclonal Antibodies Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Cancer Monoclonal Antibodies Sales Market Share in Value by Type in 2025 Figure 21. Latin America Cancer Monoclonal Antibodies Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Cancer Monoclonal Antibodies Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Cancer Monoclonal Antibodies Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Cancer Monoclonal Antibodies Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Cancer Monoclonal Antibodies Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Blood Image Figure 28. Global Blood Sales YoY Growth (2021-2032) & (k units) Figure 29. Breast Image Figure 30. Global Breast Sales YoY Growth (2021-2032) & (k units) Figure 31. Liver Image Figure 32. Global Liver Sales YoY Growth (2021-2032) & (k units) Figure 33. Brain Image Figure 34. Global Brain Sales YoY Growth (2021-2032) & (k units) Figure 35. Global Cancer Monoclonal Antibodies Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Cancer Monoclonal Antibodies Market Share by Application 2025 VS 2032 Figure 37. North America Cancer Monoclonal Antibodies Sales Market Share in Volume by Application in 2025 Figure 38. North America Cancer Monoclonal Antibodies Sales Market Share in Value by Application in 2025 Figure 39. Europe Cancer Monoclonal Antibodies Sales Market Share in Volume by Application in 2025 Figure 40. Europe Cancer Monoclonal Antibodies Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Cancer Monoclonal Antibodies Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Cancer Monoclonal Antibodies Sales Market Share in Value by Application in 2025 Figure 43. Latin America Cancer Monoclonal Antibodies Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Cancer Monoclonal Antibodies Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Cancer Monoclonal Antibodies Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Cancer Monoclonal Antibodies Sales Market Share in Value by Application in 2025 Figure 47. North America Cancer Monoclonal Antibodies Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 48. North America Cancer Monoclonal Antibodies Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Cancer Monoclonal Antibodies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Cancer Monoclonal Antibodies Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Cancer Monoclonal Antibodies Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 52. Europe Cancer Monoclonal Antibodies Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Cancer Monoclonal Antibodies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Cancer Monoclonal Antibodies Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Cancer Monoclonal Antibodies Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 56. Asia-Pacific Cancer Monoclonal Antibodies Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Cancer Monoclonal Antibodies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Cancer Monoclonal Antibodies Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Cancer Monoclonal Antibodies Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 60. Latin America Cancer Monoclonal Antibodies Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Cancer Monoclonal Antibodies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Cancer Monoclonal Antibodies Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Cancer Monoclonal Antibodies Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 64. Middle East and Africa Cancer Monoclonal Antibodies Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Cancer Monoclonal Antibodies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Cancer Monoclonal Antibodies Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Cancer Monoclonal Antibodies Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Cancer Monoclonal Antibodies Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Chimeric and Humanised Antibodies
  • Fully Humanized Antibodies
  • Murine Antibodies
  • Others
Applications
  • Blood
  • Breast
  • Liver
  • Brain
Companies covered
  • Takeda Pharmaceuticals
  • Amgen
  • F. Hoffmann-La Roche
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Cancer Monoclonal Antibodies Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Cancer Monoclonal Antibodies Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Cancer Monoclonal Antibodies Market by Type
  6. 1.3.1 Chimeric and Humanised Antibodies
  7. 1.3.2 Fully Humanized Antibodies
  8. 1.3.3 Murine Antibodies
  9. 1.3.4 Others
  10. 1.4 Global Cancer Monoclonal Antibodies Market Size by Type
  11. 1.4.1 Global Cancer Monoclonal Antibodies Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Cancer Monoclonal Antibodies Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Cancer Monoclonal Antibodies Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Cancer Monoclonal Antibodies Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Cancer Monoclonal Antibodies Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Cancer Monoclonal Antibodies Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Cancer Monoclonal Antibodies Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Cancer Monoclonal Antibodies Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Cancer Monoclonal Antibodies Industry Trends
  2. 2.2 Cancer Monoclonal Antibodies Industry Drivers
  3. 2.3 Cancer Monoclonal Antibodies Industry Opportunities and Challenges
  4. 2.4 Cancer Monoclonal Antibodies Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Cancer Monoclonal Antibodies Revenue (2021-2026)
  2. 3.2 Global Top Players by Cancer Monoclonal Antibodies Sales (2021-2026)
  3. 3.3 Global Top Players by Cancer Monoclonal Antibodies Price (2021-2026)
  4. 3.4 Global Cancer Monoclonal Antibodies Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Cancer Monoclonal Antibodies Major Company Production Sites & Headquarters
  6. 3.6 Global Cancer Monoclonal Antibodies Company, Product Type & Application
  7. 3.7 Global Cancer Monoclonal Antibodies Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Cancer Monoclonal Antibodies Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Cancer Monoclonal Antibodies Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Cancer Monoclonal Antibodies Tier 1, Tier 2, and Tier 3
4 Cancer Monoclonal Antibodies Regional Status and Outlook
  1. 4.1 Global Cancer Monoclonal Antibodies Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Cancer Monoclonal Antibodies Historic Market Size by Region
  3. 4.2.1 Global Cancer Monoclonal Antibodies Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Cancer Monoclonal Antibodies Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Cancer Monoclonal Antibodies Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Cancer Monoclonal Antibodies Forecasted Market Size by Region
  7. 4.3.1 Global Cancer Monoclonal Antibodies Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Cancer Monoclonal Antibodies Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Cancer Monoclonal Antibodies Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Cancer Monoclonal Antibodies by Application
  1. 5.1 Cancer Monoclonal Antibodies Market by Application
  2. 5.1.1 Blood
  3. 5.1.2 Breast
  4. 5.1.3 Liver
  5. 5.1.4 Brain
  6. 5.2 Global Cancer Monoclonal Antibodies Market Size by Application
  7. 5.2.1 Global Cancer Monoclonal Antibodies Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Cancer Monoclonal Antibodies Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Cancer Monoclonal Antibodies Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Cancer Monoclonal Antibodies Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Cancer Monoclonal Antibodies Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Cancer Monoclonal Antibodies Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Cancer Monoclonal Antibodies Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Cancer Monoclonal Antibodies Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Takeda Pharmaceuticals
  2. 6.1.1 Takeda Pharmaceuticals Company Information
  3. 6.1.2 Takeda Pharmaceuticals Business Overview
  4. 6.1.3 Takeda Pharmaceuticals Cancer Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Takeda Pharmaceuticals Cancer Monoclonal Antibodies Product Portfolio
  6. 6.1.5 Takeda Pharmaceuticals Recent Developments
  7. 6.2 Amgen
  8. 6.2.1 Amgen Company Information
  9. 6.2.2 Amgen Business Overview
  10. 6.2.3 Amgen Cancer Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Amgen Cancer Monoclonal Antibodies Product Portfolio
  12. 6.2.5 Amgen Recent Developments
  13. 6.3 F. Hoffmann-La Roche
  14. 6.3.1 F. Hoffmann-La Roche Company Information
  15. 6.3.2 F. Hoffmann-La Roche Business Overview
  16. 6.3.3 F. Hoffmann-La Roche Cancer Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 F. Hoffmann-La Roche Cancer Monoclonal Antibodies Product Portfolio
  18. 6.3.5 F. Hoffmann-La Roche Recent Developments
  19. 6.4 Bristol-Myers Squibb
  20. 6.4.1 Bristol-Myers Squibb Company Information
  21. 6.4.2 Bristol-Myers Squibb Business Overview
  22. 6.4.3 Bristol-Myers Squibb Cancer Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Bristol-Myers Squibb Cancer Monoclonal Antibodies Product Portfolio
  24. 6.4.5 Bristol-Myers Squibb Recent Developments
7 North America by Country
  1. 7.1 North America Cancer Monoclonal Antibodies Sales by Country
  2. 7.1.1 North America Cancer Monoclonal Antibodies Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Cancer Monoclonal Antibodies Sales by Country (2021-2026)
  4. 7.1.3 North America Cancer Monoclonal Antibodies Sales Forecast by Country (2027-2032)
  5. 7.2 North America Cancer Monoclonal Antibodies Market Size by Country
  6. 7.2.1 North America Cancer Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Cancer Monoclonal Antibodies Market Size by Country (2021-2026)
  8. 7.2.3 North America Cancer Monoclonal Antibodies Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Cancer Monoclonal Antibodies Sales by Country
  2. 8.1.1 Europe Cancer Monoclonal Antibodies Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Cancer Monoclonal Antibodies Sales by Country (2021-2026)
  4. 8.1.3 Europe Cancer Monoclonal Antibodies Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Cancer Monoclonal Antibodies Market Size by Country
  6. 8.2.1 Europe Cancer Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Cancer Monoclonal Antibodies Market Size by Country (2021-2026)
  8. 8.2.3 Europe Cancer Monoclonal Antibodies Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Cancer Monoclonal Antibodies Sales by Country
  2. 9.1.1 Asia-Pacific Cancer Monoclonal Antibodies Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Cancer Monoclonal Antibodies Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Cancer Monoclonal Antibodies Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Cancer Monoclonal Antibodies Market Size by Country
  6. 9.2.1 Asia-Pacific Cancer Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Cancer Monoclonal Antibodies Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Cancer Monoclonal Antibodies Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Cancer Monoclonal Antibodies Sales by Country
  2. 10.1.1 South America Cancer Monoclonal Antibodies Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Cancer Monoclonal Antibodies Sales by Country (2021-2026)
  4. 10.1.3 South America Cancer Monoclonal Antibodies Sales Forecast by Country (2027-2032)
  5. 10.2 South America Cancer Monoclonal Antibodies Market Size by Country
  6. 10.2.1 South America Cancer Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Cancer Monoclonal Antibodies Market Size by Country (2021-2026)
  8. 10.2.3 South America Cancer Monoclonal Antibodies Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Cancer Monoclonal Antibodies Sales by Country
  2. 11.1.1 Middle East and Africa Cancer Monoclonal Antibodies Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Cancer Monoclonal Antibodies Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Cancer Monoclonal Antibodies Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Cancer Monoclonal Antibodies Market Size by Country
  6. 11.2.1 Middle East and Africa Cancer Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Cancer Monoclonal Antibodies Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Cancer Monoclonal Antibodies Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Cancer Monoclonal Antibodies Value Chain Analysis
  2. 12.1.1 Cancer Monoclonal Antibodies Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Cancer Monoclonal Antibodies Production Mode & Process
  7. 12.2 Cancer Monoclonal Antibodies Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Cancer Monoclonal Antibodies Distributors
  10. 12.2.3 Cancer Monoclonal Antibodies Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst